With a market cap of $18.1 billion, Viatris Inc. (VTRS) is a global healthcare company focused on providing branded medicines, generic drugs, biosimilars, and over-the-counter products across more than 165 countries. Headquartered in Pennsylvania, Viatris operates a broad portfolio spanning cardiovascular, infectious disease, immunology, oncology, dermatology, and central nervous system treatments.
Shares of the company have outperformed the broader market over the past 52 weeks. VTRS stock has soared 80.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.5%. Moreover, the stock has returned 24.7% on a YTD basis, compared to SPX's 6% rise.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Looking closer, shares of the generic drugmaker have also outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 5.2% increase over the past 52 weeks and 6.1% dip in 2026.
www.barchart.com On May 5, Viatris shares popped 2.1% after the company approved a quarterly dividend of $0.12 per share for all outstanding common stock. The dividend will be paid on June 17, 2026, to shareholders of record at the close of business on May 22, 2026.
For the fiscal year that ends in December 2026, analysts expect VTRS’s adjusted EPS to grow 3.8% year-over-year to $2.44. The company's earnings surprise history is solid. It topped the consensus estimates in each of the last four quarters.
Among the 10 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on five “Strong Buy” ratings, four “Holds,” and one “Moderate Sell.”
www.barchart.com This configuration is more bullish than three months ago, with four “Strong Buy” ratings on the stock.
On Mar. 23, Barclays raised its price target on Viatris to $17 from $15 while reiterating an “Overweight” rating, citing the stock’s attractive valuation and underappreciated growth potential. The firm noted that despite a muted reaction to Viatris’ Investor Day and softer EBITDA growth expectations, the pharmaceutical company still offers significant upside, supported by its pipeline, revenue opportunities, and a strong lineup of potential catalysts heading into fiscal 2026.
The mean price target of $15.78 represents a 1.7% premium to VTRS’ current price levels. The Street-high price target of $20 implies a potential upside of 28.9% from the current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Positioning for a Big Move: SBUX Long Straddle Trade Idea Nasdaq Futures Rally on Upbeat AMD Earnings and U.S.-Iran Peace Deal Optimism As American Water Works Hikes Its Dividend, Consider Buying AWK Stock in May Pinterest Stock Skyrockets on Better-Than-Expected Earnings. Here's Why It's Not Too Late to Buy